Ligand Pharmaceuticals, Inc.

Eli Lilly and Company

Christopher M Mapes

Marcus F Boehm

Pierre-Yves Michellys

Todd Kevin Jones

Lawrence G Hamann

Robert J Ardecky

Timothy A Grese

David Andrew Neel

John S Tyhonas

Kevin Matthew Gardinier

Douglas Linn Gernert

Jyun-Hung Chen

Anthony W Thompson

Amy L Faulkner

The present invention is directed to compounds represented by Structural Formula (I) and pharmaceutically acceptable salts, solvates and hydrates thereof: (I). The invention is also directed to pharmaceutical compositions, methods of use and methods of making compounds represented by Structural Formula (I) and pharmaceutically acceptable salts, solvates and hydrates thereof.

Retinoid X receptor modulators

The present invention provides a novel class of RXR modulator compounds that exhibit an improved pharmacologic profile relative to the profile of previously studied RXR modulators, including those that share common structural features with the presently claimed modulators. The present invention also provides synthetic methods for preparing these compounds as well as pharmaceutical compositions incorporating these novel compounds and methods for the therapeutic use of such compounds and pharmaceutical compositions.

RXR modulators with improved pharmacologic profile

Growing community of inventors

San Diego, CA, United States of America

Christopher M Mapes